- AACR Investor Event time change to 6:30 p.m. ET -
- 21st Annual Needham Virtual Healthcare Conference Presentation April 13th at 1:30 p.m. ET -
SEATTLE--(BUSINESS WIRE)--Apr. 5, 2022--
Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a company presentation at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13th, 2022, at 1:30 p.m. ET/10:30 a.m. PT.
Alpine will host a virtual investor event on April 12th, 2022, at 6:30 p.m. ET, to coincide with the 2022 American Association for Cancer Research (AACR) Annual Meeting. The meeting will commence 30 minutes later than previously announced and will begin at 6:30 p.m. ET.
A live webcast of both events will be available online in the investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events. A replay of each presentation will be available on the company website for 90 days following the webcast.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405006140/en/
Director, Investor Relations and Corporate Development
Alpine Immune Sciences, Inc
Source: Alpine Immune Sciences Inc.